Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Study of Lu AG06466 MAGL Occupancy in Healthy Men
NCT04419636Phase 1Completed
- Sponsor
- Lundbeck
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ABX-1431 in Tourette syndrome (TS), post-traumatic stress disorder (PTSD) and spasticity (2 arms), sponsored by Lundbeck. Primary endpoint: Central monoacylglycerol lipase (MAGL) occupancy. Started May 2020; status: completed.
02
Drugs
ABX-1431
03
Conditions
Tourette syndrome (TS)post-traumatic stress disorder (PTSD)spasticity
Beyond the preview
Go deeper on NCT04419636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419636.